| Ocrelizumab - Wikipedia, the free encyclopedia Ocrelizumab is a humanized anti- CD20 monoclonal antibody. It targets mature B lymphocytes and hence is an immunosuppressive drug candidate. It is under development ... Read More |
| Medical News: Ocrelizumab Shows Promise in MS - in Clinical ... In order to receive your certificate of participation, you should read the information about this activity, including the disclosure statements, review the entire ... Read More |
| Roche, Biogen shutter blockbuster ocrelizumab arthritis program ... Once tapped as a likely blockbuster, Roche and Biogen Idec have opted to kill their ambitious late-stage development program of ocrelizumab as a treatment for ... Read More |
| GEN | Insight & Intelligence™: Ocrelizumab: One Size Does Not ... On March 8, Roche and Biogen Idec said that they were suspending treatment of rheumatoid arthritis (RA) patients with Ocrelizumab. It reportedly caused serious and ... Read More |
| Ocrelizumab - Top 10 Phase III Failures - FierceBiotech The drug: OcrelizumabThe disease: Rheumatoid arthritisThe company: Roche At the end of 2009, ocrelizumab looked every inch of a blockbuster for rheumatoid arthritis. Read More |
| Phase II Study Showed Ocrelizumab Maintained Significant Reduction ... Phase III Trials Underway to Investigate Ocrelizumab in Two Forms of MS Oct 20, 2011 - Genentech, a member of the Roche Group (SIX RO, ROG OTCQX RHHBY), today a Read More |
| Ocrelizumab Shows Significant Reduction in Multiple Sclerosis ... » Health and Disability » Autoimmune Diseases » » Multiple Sclerosis. Ocrelizumab Shows Significant Reduction in Multiple Sclerosis Disease Activity Read More |
| Ocrelizumab drug holds promise for multiple sclerosis An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating ... Read More |
| Ocrelizumab Results in MS Published October 31, 2011 — Results of a phase 2 trial of ocrelizumab treatment in patients with relapsing-remitting multiple sclerosis (MS) show that both doses studied ... Read More |
| Roche - Roche and Biogen Idec announce their decision to ... Basel, 19 May 2010. Roche and Biogen Idec announce their decision to discontinue the ocrelizumab clinical development programme in patients with rheumatoid arthritis Read More |
